









Agios Pharmaceuticals Q2 revenue beats estimates

ReutersJul 31, 2025 10:47 AM

Overview

Agios Q2 2025 product revenue rises to $12.5 mln, beating analyst expectations
Co ends Q2 with $1.3 bln in cash, down from $1.5 bln at year-end 2024
Agios prepares for potential U.S. approval of PYRUKYND for thalassemia in Sept 2025

Outlook

Agios expects PYRUKYND approval for thalassemia by September 7, 2025

Result Drivers

PYRUKYND SALES - Generated $12.5 mln in Q2 2025, up from $8.6 mln in Q2 2024, driven by increased patient enrollment
EUROPEAN EXPANSION - Entered distribution agreement with Avanzanite Bioscience for PYRUKYND sales in European markets

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Product Revenue	Beat	$12.46 mln	$9.48 mln (8 Analysts)
Q2 EPS		-$1.93
Q2 Net Income		-$112.02 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $53.50, about 29.8% above its July 30 closing price of $37.54

Press Release: ID:nGNX8Q59wR

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

Goldman Sachs Raises US Recession Probability, What Are the Reasons?

TradingKey - Goldman Sachs recently raised the probability of a U.S. recession over the next 12 months to 30%. While this adjustment may appear to be a mere numerical change, within the current macroeconomic context, it signals a shift in sentiment—market confidence in a "soft landing" for the U.S.

Buffett’s Berkshire Increases Bets on Japanese Stocks. Spends 287.4 Billion Yen for 2.49% Strategic Stake in Tokio Marine Holdings

TradingKey - Against the backdrop of global capital re-evaluating asset allocation paths, Berkshire Hathaway (BRK.B) has once again increased its exposure to the Japanese market. Latest disclosures reveal that the company, through its reinsurance entities, invested 287.4 billion yen (approximately $1.8 billion) to strategically acquire a 2.49% stake in Tokio Marine Holdings, while simultaneously establishing a long-term partnership between the two parties.

Why Invest In AI? What Are The Best AI Stocks To Buy In 2026?

TradingKey - The appeal of AI as an investment theme has amplified over recent years. There are strong underlying reasons on why AI is one of the hottest themes currently – primary reason being the increased usability of AI in many practical use-cases which wasn’t the case earlier. Consequently, AI

Conflict Escalates: Trump Issues Ultimatum as Goldman Warns of Record $147 Oil

TradingKey - Middle East conflicts escalated sharply over the weekend. Brent crude rose over 1% intraday, with prices surging to near $109 at the time of publication. As the U.S.-Iran conflict enters its fourth week with no signs of de-escalation, Goldman Sachs has once again raised its oil price fo

Gold Slumps $800 Over 4 Consecutive Days: Safe-Haven Demand Remains, Why Are Gold Prices Still Falling?

TradingKey - Gold continued its weak correction today as the market remained under pressure from the combined impact of geopolitical risks, a strengthening US dollar, and rising US Treasury yields. Although safe-haven sentiment persists, capital is clearly prioritizing the avoidance of pressure from

Tradingkey

KeyAI

